Clinical Trials Logo

Clinical Trial Summary

Restless Leg Syndrome (RLS) is a sensory-motor problem characterized by an uncomfortable and unpleasant feeling that causes a strong and overwhelming desire to move the legs, usually during periods of inactivity during sleep.It is reported that pregnancy is an important risk factor in the onset and worsening of RLS.Individuals with RLS avoid social activities, often experience psychiatric problems such as depression, anxiety disorders, and chronic sleep disorders. Therefore, restless leg syndrome significantly affects daily life and coping with these problems. Individuals with RLS initially undertake a variety of non-pharmacological practices to relieve symptoms.Progressive muscle relaxation exercises, reducing the level of epinephrine and norepinephrine in the blood and heart rate, reducing oxygen consumption, regulating metabolic rate, lowering blood pressure, reducing muscle tension, preventing fatigue and restlessness, decreasing pain by increasing endorphin levels, increasing coping with pain and stress, It has many benefits such as improving sleep and quality of life.This study will be conducted to evaluate the effect of progressive muscle relaxation exercise training and follow-up given to pregnant women with restless leg syndrome on the severity of restless leg syndrome, quality of life associated with restless legs syndrome, and sleep quality.


Clinical Trial Description

Restless Leg Syndrome (RLS) is a sensory-motor problem characterized by an uncomfortable and unpleasant feeling that causes a strong and irresistible desire to move in the legs, usually during periods of inactivity during sleep. Depending on cultural, environmental and genetic differences, the prevalence of RLS is reported to be the highest in North America and Europe, ranging from 5.5% to 11.6%, and this prevalence is reported to be between 1.0 and 7.5% in Asia. Turkey made society based on two studies in RLS prevalence of respectively 3.19% and 7% were found. HBS 's with age, e increases from and in women has been reported from two times higher than that seen in man. The reason for its higher incidence in women has not been clearly explained, but it has been thought to be related to hormonal changes during pregnancy, menstruation and menopause. In a systematic review and meta-analysis study, it was reported that the prevalence of RLS in pregnant women worldwide is 21% and the symptoms are more common in the third trimester. In our country, g is reported to vary between midwives in HBS 19-26% incidence. In the study conducted by Neyal et al. (2015) in our country, it was found that 15.6% in the first trimester of pregnancy; 32.8 % in the second trimester ; It is reported that RLS symptoms are observed with a rate of 38.8% in the third trimester and the symptoms continue at a rate of 34.8% after birth. In the study conducted by AkbaĊŸ and Yaman Sözbir (2019), approximately half of the pregnant women (46.4%) had RLS symptoms and the RLS severity mean score of pregnant women with RLS was found to be 20.82 ± 6.61 . In the same study, the HBS of 49.1% of women with severe and very Siddiqui has been determined that there is live meat that fell to the severity of RLS increases quality of life reported and un. Pregnancy is reported to be an important risk factor in the onset and worsening of RLS. It has been proven that the dopaminergic system plays an important role in the pathogenesis of RLS . Iron acts as a cofactor in the synthesis and formation of dopamine and normal dopamine production is impaired in iron deficiency. It is reported that increased iron need and anemia during pregnancy triggers RLS and the problem gets worse in the third trimester of pregnancy. In addition, vitamin D and folate increase dopamine synthesis and are reported to be protective of dopaminargic neurons and the brain against metabolite toxins. Studies have shown that iron , folate, and vitamin D deficiency cause restless leg syndrome. In addition, increasing estrogen, progesterone and prolactin levels during pregnancy accelerate the appearance of symptoms, especially in the third trimester. It has been reported that estrogen inhibits the synthesis and release of dopamine during pregnancy and progesterone increases neuronal excitability, leading to frequent hyper- reflexes and periodic leg movements and RLS during pregnancy. After birth, with the rapid increase of prolactin hormone, symptoms begin to improve. Individuals with RLS avoid social activities, often experience psychiatric problems such as depression, anxiety disorders, and chronic sleep disorders. Therefore, restless leg syndrome significantly affects daily life and coping with these problems . HBS to relieve symptoms of various individuals who initially non-pharmacological located in the application s . However, it may be necessary to benefit from pharmacological treatment in cases with severe RLS. However, the use of drugs in pregnant women may be inconvenient. A standard drug therapy has not been determined for the treatment of RLS in pregnant women and the number of drugs that can be used is limited. Because most drugs have been used according to the evidence of non-pregnant patients and controlled studies in the treatment of RLS during pregnancy are insufficient. Therefore, GeBa steel during treatment of RLS in terms of drug therapy with the benefits of fetal compromise between the advantages/disadvantages of evaluation and decision making in this regard is necessary . However, during the treatment of RLS in pregnancy, the effect of drugs on the fetus , especially putting njenital me lformasyo considering the possibility should be taken. The purpose of progressive relaxation exercises; It is to learn to feel the difference between tension and looseness in our body and to relax by ourselves in our daily life. For this purpose, the most widely used muscle groups, hands, arms, neck, shoulders, face, chest, abdomen, hips, feet and fingers were run . This method, which is applied in the form of stretching and relaxing the muscles , enables people to learn where their muscles are, what they have become during tension, and the difference when this tension disappears. Progressive muscle relaxation exercises, reducing the level of epinephrine and norepinephrine in the blood and heart rate, reducing oxygen consumption, regulating metabolic rate, lowering blood pressure, reducing muscle tension, preventing fatigue and restlessness, reducing pain by increasing endorphin levels, increasing coping with pain and stress, It has many benefits such as increasing the quality of sleep and life. RLS, which increases in frequency during pregnancy, disrupts sleep quality and affects the quality of life as it increases fatigue in pregnant women. During the follow-up, care and counseling process performed by nurses during pregnancy, pregnant women should be evaluated for sleep disturbance, fatigue, anxiety and stress that may be caused by RLS and attempts should be made to increase the quality of life by solving problems in cases . At this point, it is especially important to teach how to deal with RLS or how to relieve symptoms . In this context, progressive muscle relaxation exercises, which have many benefits and can be applied by nurses, should be taught to pregnant women during the routine follow-up and care process, and the use of relaxation exercises should be provided both at home and in clinics. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04853771
Study type Interventional
Source Gazi University
Contact Pinar AKBAS
Phone +90 (505) 127 90 14
Email [email protected]
Status Recruiting
Phase N/A
Start date April 6, 2021
Completion date January 6, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04786314 - The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome N/A
Completed NCT01455012 - Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome Phase 4
Terminated NCT01192503 - Safety and Efficacy of Rasagiline in Restless Legs Syndrome Phase 2/Phase 3
Completed NCT00530530 - ASP8825 - Study in Patients With Restless Legs Syndrome Phase 2
Completed NCT00721279 - Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome N/A
Completed NCT00942253 - Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS) Phase 2
Completed NCT00375284 - A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS Phase 4
Completed NCT00479531 - Sequential Compression Devices for Treatment of Restless Legs Syndrome Phase 3
Active, not recruiting NCT03218969 - Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist Phase 1/Phase 2
Withdrawn NCT03849001 - Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS N/A
Completed NCT03076541 - Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements. N/A
Completed NCT02532608 - Infra-slow Oscillations During Sleep N/A
Completed NCT01528462 - Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke N/A
Completed NCT00748098 - Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance Phase 3
Completed NCT00373542 - 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome Phase 4
Completed NCT00355641 - Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome Phase 3
Completed NCT00275457 - Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients Phase 3
Completed NCT00239486 - Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS) Phase 2
Completed NCT01887613 - Specified Drug Use-Results Survey of Regnite
Terminated NCT00996944 - Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration) Phase 2